Metraipolis › archive › dc_be579be05478
Reduced-Dose Pazopanib as First-Line Therapy in Metastatic Renal Cell Carcinoma: Real-World Outcomes and Subsequent Treatment Patterns from a… — Europe PMC PMID:42745780
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42745780
- DOI
- 10.15586/jkc.v13i3.495
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-08T04:50:55.644Z
- SHA-256 of the archived text
07ec755cfb79fca53dd6712dc10d24a75a4efa6ad59b787b6ee0ab70b86e7b39- Stable URL of this page
https://metraipolis.com/documento/dc_be579be05478
How to cite
Reduced-Dose Pazopanib as First-Line Therapy in Metastatic Renal Cell Carcinoma: Real-World Outcomes and Subsequent Treatment Patterns from a… — Europe PMC PMID:42745780 — Europe PMC (en), https://europepmc.org/article/MED/42745780 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_be579be05478 (Metraipolis archive dc_be579be05478, sha256 07ec755cfb79fca53dd6712dc10d24a75a4efa6ad59b787b6ee0ab70b86e7b39)
BibTeX
@misc{dcbe579be05478,
title = {Reduced-Dose Pazopanib as First-Line Therapy in Metastatic Renal Cell Carcinoma: Real-World Outcomes and Subsequent Treatment Patterns from a… — Europe PMC PMID:42745780},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42745780},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_be579be05478; sha256 07ec755cfb79fca53dd6712dc10d24a75a4efa6ad59b787b6ee0ab70b86e7b39},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42745780. Agents can read the archived copy with the MCP tool read_document.